Background {#Sec1}
==========

Wilms tumor, aniridia, genitourinary anomalies and mental retardation (WAGR) syndrome is a rare genetic disorder caused by the chromosomal defect at 11p13.3 \[[@CR1]\]. Genetically, segmental deletions encompassing the *WT1* and *PAX6* genes are known to cause the syndromic phenotype, while an accompanying phenotype of obesity is linked to the extensive deletion involving the *brain-derived neurotrophic factor* (*BDNF*) locus \[[@CR2]\]. Thus, patients with the WAGR and obesity (O) phenotypes are designated as having WAGRO syndrome \[[@CR2]\].

Imprinting-associated disorders commonly present with abnormal physical growth and autism. Prader-Willi syndrome is an example of such diseases that are phenotypically characterized by muscular hypotonia in infancy, short stature and hyperphagic behavior with cognitive impairment later in childhood \[[@CR3]\]. Although autistic and hyperphagic behaviors are known to overlap between WAGRO and Prader-Willi syndromes, no information is currently available for epigenetic impacts of BDNF insufficiency on gene expression in the developing brain of humans and animals. This study was thus directed to test whether WAGRO syndrome might have deregulated conditions in neuroendocrine or methylation profiles.

Case presentation {#Sec2}
=================

A 1-year and 10-month-old girl was referred to our department for assessment of growth delay and absence of speech. She was born at the 41st week of gestational age with birth weight of 2950 g. Congenital aniridia, cataracts and macular hypoplasia were noticed at birth. Genitourinary apparatus was normal in appearance.

When she was first referred to our department at 1 year and 10 months of age, her height (74.4 cm, −2.8SD) and weight (8.5 kg, −3.3SD) were evaluated to be small for age. At this age, her motor skills and cognitive development were considered as low as 10 months of age. She developed bilateral renal tumors at 2 years and 1 month of age, for which surgical resection was conducted. Pathological examination confirmed the diagnosis of Wilms tumor. The renal tumors responded favorably to standard regimens of chemotherapy. She was well nourished without recurrence of tumors for over 4 years after the chemotherapy. Thus, the clinical features of this case fit to the typical phenotypes of WAGR syndrome, as previously reported \[[@CR1], [@CR2], [@CR4]\].

The G-band test revealed the karyotype of 46,XX,del(11)(p11.2p14) (Fig [1a](#Fig1){ref-type="fig"}). An array-comparative genome hybridization analysis (Clinical Microarray ver. 8.1 at Baylor MGL), and found the 14.5-Mb deletion at 11p14.3p12 (Fig [1a](#Fig1){ref-type="fig"}). The minimal segment of deletion were defined as arr\[GRCh37\] 11p14.3p12(24,792,569_39,222,929)×1. According to the GRCh37/hg19 assembly, the deleted region was located at the chromosomal band, 11p14.3p12. The deleted interval involved 50 genes in the adjacent loci, including *PAX6* (chr11:31,806,340--31,839,509) and *WT1* (chr11:32,409,322--32,457,081). The heterozygous deletions of *WT1* and *BDNF* were validated with FISH and qPCR analyses (Fig. [1b, c](#Fig1){ref-type="fig"}; see Additional file [1](#MOESM1){ref-type="media"}). We further excluded that this patient had a variant coding sequence of *BDNF* at the non-deleted allele (data not shown). Together, these data indicate that the heterozygous deletion of *BDNF*, but not a hypomorphic mutation, such as Val66Met variant \[[@CR5]\], caused the developmental delay in this patient. Because we were not allowed to analyze the parental chromosomes, it remained to be determined whether the deletion occurred de novo or as the consequence of chromosomal defects with lower penetrance, such as balanced translocations.Fig. 1Genetic analyses of the present cases. **a** Array-CGH data for the present case. The left-top panel depicts the abnormal G-band pattern (arrow) of chromosome 11 in the peripheral leukocytes. On the right top, the log~2~ values of relative copy numbers are plotted against the base position (x10E6) at chromosome 11. Color codes represent gain (green) or loss (red) of the probed regions. The horizontal dashed lines indicate the thresholds of duplication (0.5) and heterozygous deletion (−1.0). The lower-panel shows a magnified view of the deleted region. G-band locus (thick, black and gray lines) and protein-coding genes (blue boxes) are mapped on the coordinates available at the UCSC genome browser (GRCh37/hg19). Chromosomal locations of the three WAGR syndrome-associated genes (*BDNF*, *PAX6* and *WT1*) are denoted under the diagram. **b** The FISH image. The green (arrowheads) and red (arrows) signals show *CCND1* (control) and *WT1* loci, respectively. Note that one copy of the *WT1* (arrow) is missing while the two copies of *CCND1* signals (arrowheads) are unaffected. **c** Quantitative PCR data for this case and a healthy control. *PRMT3* (chr11:20,409,076--20,530,879) serves as an internal control. Bar plots show the relative copy numbers of *WT1, PAX6* and *BDNF* (mean ± SD, *n* = 4) to that of *PRMT3* for each individual

At 5 years of age, she reached 91.3 cm (−3.5 SD) of height and 12.45 kg (−2.2 SD) of body weight. She had recurrent episodes of ketogenic hypoglycemia on starvation. To assess whether she may have neuro-endocrine dysfunction, we conducted a series of hormonal loading tests. Insulin tolerance test (0.1 U/kg) revealed that her blood glucose rapidly declined to 35 mg/dl after infusion, while growth hormone (GH), adrenocorticotropic hormone (ACTH) and cortisol were all normally increased in response to the hypoglycemic condition at 15--30 min (Additional file [1](#MOESM1){ref-type="media"}: Figure S2A). Combined infusion of 500 μg/kg L-arginine, 1.5 μg/kg CRH and 10 μg/kg TRH induced normal patterns of release in corresponding hormones (Additional file [1](#MOESM1){ref-type="media"}: Figure S2B). Oral glucose tolerance test with 1.75 g/kg of glucose resulted in normally fluctuated blood glucose and insulin levels, while lactate and pyruvate did not show abnormal patterns of accumulation (Additional file [1](#MOESM1){ref-type="media"}: Figure S2C). These data reassured that she had no obvious predisposing causes for hypoglycemia. She was likely intolerant of starved conditions owing to immature energy homeostasis as frequently observed in preschool children, but not as a consequence of WAGR-relevant phenotype.

This case had typical growth and neurodevelopmental profiles as WAGR syndrome with large chromosomal deletions (Table [1](#Tab1){ref-type="table"}) \[[@CR1]\]. We therefore considered it valuable to characterize her epigenetic profiles, which might disclose one of molecular mechanisms for delays in postnatal growth and development in WAGR syndrome. Recent studies indicated that chromosomal defects in the WAGR-critical region encompassed the *LGR4* gene \[[@CR6]\]. The heterozygous deletion of *LGR4* was reported to cause the secondary effects on the epigenetic status through disturbing the expression of chromatin modifier proteins. Towards this end, we investigated whether children with WAGR syndrome might bear aberrant methylation profiles on previously known imprinting regions. However, this case had normal methylation patterns at known loci for imprinting-associated disorders when using lymphocytes (Additional file [1](#MOESM1){ref-type="media"}: Table S1) \[[@CR7]\]. CARE guidelines were followed in reporting this case.Table 1Phenotypic spectrum of WAGR syndrome with 10 Mb or larger deletionsNoCase IDAgeSexReference (Author, Year)CytobandSize (Mb)Genome\
AssemblyStart pointEnd pointHeightBody\
weightNeurological Signs^*a*^1F24a16FXu S, 2008 \[[@CR4]\]11p12p15.123.0GRCh 35 (hg17)20,040,41943,071,919NANAID, OCD2F8a11FXu S, 2008 \[[@CR4]\]11p14p12.319.1GRCh 35 (hg17)25,086,50144,212,278NANAID, OCD, ASD3NIH106MXu S, 2008 \[[@CR4]\]11p11.2p14.118.2GRCh 35 (hg17)27,656,70045,858,752NANADD4F17a36FXu S, 2008 \[[@CR4]\]11p14p12.315.6GRCh 35 (hg17)25,086,50140,651,423NANAID, ASD, ADHD,\
OCD, Anxiety5NIH34MXu S, 2008 \[[@CR4]\]11p14p12.315.3GRCh 35 (hg17)24,202,90939,529,029NANADD6F10a7FXu S, 2008 \[[@CR4]\]11p11.2p1314.9GRCh 35 (hg17)31,284,41446,194,871NANAID, DD, OCD,\
Anxiety7F20a15MXu S, 2008 \[[@CR4]\]11p14p12.314.6GRCh 35 (hg17)25,844,57140,482,022NANAID, DD, ASD,\
ADHD, OCD,\
Anxiety8YS 0135F\[This study\]11p14.3p1214.4GRCh37 (hg19)24,792,56939,222,92991.3 cm\
(−3.5 SD)12.45 kg\
(−2.2 SD)DD, ASD,\
Hyperphagia9NIH97FXu S, 2008 \[[@CR4]\]11p13p15.114.4GRCh 35 (hg1720,759,56035,124,532NANAID, ASD10F7a13FXu S, 2008 \[[@CR4]\]11p14p12.314.3GRCh 35 (hg1724,542,32138,824,714NANAASD, DD, ADHD11NIH617MXu S, 2008 \[[@CR4]\]11p14p12.214.2GRCh 35 (hg1726,005,13440,174,102NANAID, ASD, ADHD,\
Anxiety12NIH219MXu S, 2008 \[[@CR4]\]11p13p15.113.5GRCh 35 (hg1720,135,62133,614,001NANAID, ASD13F3a26FXu S, 2008 \[[@CR4]\]11p12p1312.9GRCh 35 (hg1731,284,41444,212,278NANAID, DD, Seizure,\
Depression14F21a12FXu S, 2008 \[[@CR4]\]11p14p12.312.5GRCh 35 (hg17)25,336,59337,873,278NANAADHD, OCD,\
Anxiety15F14a12FXu S, 2008 \[[@CR4]\]11p14p12.112.2GRCh 35 (hg17)28,001,85340,239,548NANAID, ASD, OCD,\
Anxiety, ADHD16F1a11MXu S, 2008 \[[@CR4]\]11p13p14.311.4GRCh 35 (hg17)24,848,85536,266,146NANAID, ASD, Anxiety,\
OCD17NIH114MXu S, 2008 \[[@CR4]\]11p14p12.210.7GRCh 35 (hg17)26,690,77837,341,623NANAID, ASD18F23a16MXu S, 2008 \[[@CR4]\]11p14p12.110.6GRCh 35 (hg17)27,675,63438,235,380NANAID, ASD, DD, OCD19Patient 22FYamamoto T,\
2013 \[[@CR13]\]11p13p1210.5GRCh 35 (hg17)32,990,62743,492,58075.6 cm\
(−3.5SD)11.9 kg\
(+0.8SD)DD20NIH126MXu S, 2008 \[[@CR4]\]11p14p12.110.2GRCh 35 (hg17)27,692,63537,916,281NANAID, ASD21F19a5MXu S, 2008 \[[@CR4]\]11p14p12.210.1GRCh 35 (hg17)26,699,47536,757,882NANAID, DD, ASD^a^ *Abbreviations*: *ID* intellectual disability, *OCD* obsessive compulsive disorder, *ASD*, autism spectrum disorder, *DD*, developmental delay, *ADHD*, attention deficit hyperactive disorder

Discussion and conclusions {#Sec3}
==========================

We described a girl with typical phenotypes of WAGR syndrome. By defining the deleted interval in the short arm of chromosome 11, we confirmed that she had heterozygous deletions of *WT1*, *PAX6* and *BDNF1*. The *BDNF* gene encodes brain-derived neurotrophic factor, one of the most potent activators of neurogenesis and synaptogenesis in the central nervous system \[[@CR8]\]. Precise mechanisms for developing the obesity phenotype with *BDNF* deletion remain to be elusive; however, hypothalamic dysfunctions due to hypomorphic mutation of *BDNF* have been proposed in both humans and animal models \[[@CR9], [@CR10]\]. Although our case did not show hyperphagic behaviors during this study period, her metabolic status may be deranged to drive this phenotype in later stages.

BDNF and its cognate receptor, tyrosine receptor kinase B (TrkB), coordinate glucose metabolism and energy homeostasis in the hypothalamus \[[@CR11], [@CR12]\]. Because we were unable to detect hyper- or hypo-functioning responses to hormonal loading tests in this case, she was likely to experience hypoglycemic episodes on starvation without specific causes in the neuro-endocrine system. However, one could still argue that such hypothalamic dysfunctions might be evident only when she develops obesity. Thus, serial observation of physical growth and its correlation with hyperphagic and autistic behaviors in childhood through adolescence will be necessary to clarify the neural bases for obese phenotype of WAGR syndrome.

We further verified that she had unaltered methylation profiles at the CpG sites of previously known imprinting genes. Although it still remains unknown why the segmental deletion at 11p15 lead to short stature in WAGR syndrome in early childhood, these data provide a clue for directing future epigenetic study on WAGR syndrome. Consecutive evidence in future studies will warrant these data and provide insight into genotype-phenotype correlations for children with WAGR syndrome.

Additional file {#Sec4}
===============

Additional file 1:For cytogenetics, quantitative PCR for copy number and gene expression analyses, methylation analysis, and ethics statement. Figure S1. Neuro-endocrine profile of the present case. Table S1. Methylation profile of the present case. Additional file References 1--3. (PDF 652 kb)
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